AI in Real-World Studies Webinar aims to deliver the landscape overview of advances in the evidence-based medicine industry, including current trends, key players, and opportunities for further business development.
Real-World Data (RWD) and Real-World Evidence (RWE) enable companies to speed up research, improve data analysis, evaluate trends and patient outcomes, and even increase commercial success. This results in accelerated drug development that will faster provide patients with new treatments. Statistically, the real-world studies and evidence industry has excellent potential for growth in 2022-2023.
Deep Pharma Intelligence and The Yuan will deliver keynote speeches focusing on the real-world data (RWS) business in Asia and globally, new trends, leading companies with cutting-edge technology, and shareholders in the industry. Numerous infographics and mind maps accompanying the data will be featured on the Deep Pharma Intelligence dashboard.
The primary goal of this webinar was to give a complete picture of the industry environment in terms of AI usage in drug discovery, clinical research, and other elements of pharmaceutical research and development.
This webinar was designed to guide you through what is going on in this industry right now and potentially predict what will happen next.
Deep Pharma Intelligence held a virtual event (November 23), which was a unique opportunity share our findings from a unique market study revealing R&D platforms for developing therapeutic cancer vaccines, the key players in each category, the science behind the development, and case studies illustrating opportunities and challenges of each research strategy.
On November 15th - 17th 2021 Deep Pharma Intelligence (DPI) hosted three virtual events that were focused on key industry trends, activities, and investing takeaways in the artificial intelligence (AI) in the Pharma sector.